Analyzing the Future of Phenylketonuria (PKU) Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the phenylketonuria (pku) market right now?
The market size for phenylketonuria (PKU) has experienced significant growth in the past few years. Projected to rise from $0.85 billion in 2024 to $0.93 billion in 2025, it has a compound annual growth rate (CAGR) of 9.1%. Factors contributing to this growth include the expansion of newborn screening programs, increased consciousness about metabolic disorders, management of PKU through diet, wider access to medical foods, and the greenlight from regulatory bodies for PKU treatments.
How fast Is the phenylketonuria (pku) market expected to grow, and what’s its future value?
In the coming years, the phenylketonuria (PKU) market is set to experience significant growth, expected to reach $1.30 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.8%. The projected growth during the forecast period is primarily due to the increased uptake of gene therapy, growth of enzyme replacement therapies, amplified investment in research on rare diseases, and escalating demand for personalized medicine, along with government-initiated PKU treatment coverage. Additionally, the expected key trends of the forecast period include the introduction of RNA-based therapies, the application of digital health solutions for managing PKU, growing partnerships between biotechnology firms and research institutes, a shift towards non-dietary treatment options, as well as the broadening scope of telehealth services for PKU patients.
Get your phenylketonuria (pku) market report here!
https://www.thebusinessresearchcompany.com/report/phenylketonuria-pku-global-market-report
What are the leading drivers of growth in the phenylketonuria (pku) market?
As the incidence of genetic disorders continues to rise, it’s anticipated to fuel the expansion of the phenylketonuria (PKU) market in the future. Genetic disorders are health issues resulting from DNA irregularities, such as genetic mutations, gene or chromosome deletions or duplications. Several factors contribute to the growing number of genetic disorders, including higher maternal age, environmental impact, advancements in diagnosis technology, and an increased level of awareness resulting in improved detection rates. Phenylketonuria plays a crucial role in comprehending genetic disorders by showing how inherited enzyme deficiencies could result in serious metabolic issues. For example, according to a report by Gene People, a registered charity based in the UK, in March 2024, roughly 1 in 25 children are affected by genetic conditions, impacting above 2.4 million children and adults in the UK. Furthermore, nearly 30,000 infants and children in the UK are diagnosed with a genetic condition annually. Hence, the surge in genetic disorders is propelling the growth of the phenylketonuria (PKU) market.
What are the key segments defining the phenylketonuria (pku) market?
The phenylketonuria (PKU) market covered in this report is segmented –
1) By Type: Hyperphenylalaninemia, Mild Phenylketonuria (PKU), Moderate And Variant, Classic Phenylketonuria (PKU)
2) By Treatment Type: Enzyme Replacement Therapy, Gene Therapy, Medication, Dietary Therapy
3) By Diagnosis: Genetic Testing, Biochemical Testing, Newborn Screening
4) By End-User: Specialty Clinics, Research Institutes, Home Healthcare, Hospitals
Subsegments:
1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia, Moderate Hyperphenylalaninemia, Severe Hyperphenylalaninemia
2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management, Mild PKU with enzyme supplementation
3) By Moderate And Variant: Moderate PKU with medication, Variant PKU with treatment variations
4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management, Classic PKU with enzyme replacement therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21257&type=smp
Who are the key players steering the development of the phenylketonuria (pku) market?
Major companies operating in the phenylketonuria (PKU) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company, LLC, Relief Therapeutics Holding SA, SOM Innovation Biotech S.A., Synlogic Inc., Galen Ltd, Aptatek Biosciences Inc., Homology Medicines Inc
What key trends are currently impacting the phenylketonuria (pku) market’s development?
Key corporations in the phenylketonuria (PKU) market are prioritizing creating cutting-edge products with assorted technologies, such as physiomimic technology, to bolster the effectiveness and safety of PKU therapies by recreating human physiological conditions for enhanced drug absorption and metabolism. Physiomimic technology incorporates an all-encompassing set of hardware, consumables, and testing protocols with the objective to mirror complex human biology and precisely forecast human drug reactions. To illustrate, in October 2022, a Switzerland-based biopharmaceutical firm called Relief Therapeutics Holding SA announced the release of PKU Golike. This new age medical food product, PKU Golike, has been developed using the patented, pharmaceutical-grade Physiomimic technology for managing the dietary requirements of phenylketonuria (PKU) patients. PKU Golike is a protracted-release amino acid product that comes in the form of granules, packets, and medical food bars. Its distinctive coating allows for the physiological absorption of amino acids, resembling natural proteins, while hiding their foul taste, smell, and aftertaste.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21257
Which regions are most influential in expanding the phenylketonuria (pku) market?
North America was the largest region in the phenylketonuria (PKU) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the phenylketonuria (PKU) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Pulmonary Embolism Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report
Pulmonary Arterial Hypertension Global Market Report 2025
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
